Author: admin

The Frontotemporal Dementia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Frontotemporal Dementia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.

Some of the key takeaways from the Frontotemporal Dementia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Frontotemporal Dementia treatment therapies with a considerable amount of success over the years. 
• Frontotemporal Dementia companies working in the treatment market are Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others, are developing therapies for the Frontotemporal Dementia treatment 
• Emerging Frontotemporal Dementia therapies in the different phases of clinical trials are- Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others are expected to have a significant impact on the Frontotemporal Dementia market in the coming years.   
• In December 2023, The Danish biotechnology company, Vesper Bio, has administered the initial dose to the first participant in a Phase I trial assessing the oral medication VES001 for frontotemporal dementia (FTD). This randomized, double-blind trial aims to evaluate the safety and tolerability of Vesper Bio’s compound, VES001, which the company describes as a first-of-its-kind brain-penetrating medication.
• In February 2022, The completion of a Series B fundraising for $64 million was announced by Arkuda Therapeutics. Together with Eli Lilly and Company, Surveyor Capital (a Citadel company), and current investors Pfizer Ventures, Tekla Capital Management LLC funds, Mission BioCapital, and Atlas Venture, Cormorant Asset Management and Pivotal bioVenture Partners co-led the financing.
• In January 2022, The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF) announced their collaboration to support Wave Life Sciences’ FOCUS-C9 Phase 1b/2a clinical trial, which looks into WVE-004 as a possible treatment for amyotrophic lateral sclerosis (C9-ALS) and C9orf72-associated frontotemporal degeneration (C9-FTD).

Frontotemporal Dementia Overview

Frontotemporal dementia (FTD) is a collective term for a set of disorders caused by gradual loss of function in the brain’s frontal and temporal lobes. These brain regions are crucial for behavior, language, and decision-making skills.

Get a Free Sample PDF Report to know more about Frontotemporal Dementia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight

Emerging Frontotemporal Dementia Drugs Under Different Phases of Clinical Development Include:

• Research programme CNS Therapies: Deep Genomics
• Research Program M1 PAM: Asceneuron SA
• AVB-101: AviadoBio
• Research programme CNS: CAMP4 Therapeutics
• NI308: Neurimmune
• PR006: Prevail Therapeutics
• PBFT02: Passage Bio
• TPN-101: Transposon Therapeutics
• AL001: Alector Inc.

Frontotemporal Dementia Route of Administration

Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Frontotemporal Dementia Molecule Type

Frontotemporal Dementia Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Frontotemporal Dementia Pipeline Therapeutics Assessment

• Frontotemporal Dementia Assessment by Product Type
• Frontotemporal Dementia By Stage and Product Type
• Frontotemporal Dementia Assessment by Route of Administration
• Frontotemporal Dementia By Stage and Route of Administration
• Frontotemporal Dementia Assessment by Molecule Type
• Frontotemporal Dementia by Stage and Molecule Type

DelveInsight’s Frontotemporal Dementia Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Frontotemporal Dementia product details are provided in the report. Download the Frontotemporal Dementia pipeline report to learn more about the emerging Frontotemporal Dementia therapies

Some of the key companies in the Frontotemporal Dementia Therapeutics Market include:

Key companies developing therapies for Frontotemporal Dementia are – Alector Inc., Transposon Therapeutics, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio, Inc., Prevail Therapeutics, Wave Life Sciences, and others.

Frontotemporal Dementia Pipeline Analysis:

The Frontotemporal Dementia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Frontotemporal Dementia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia Treatment.
• Frontotemporal Dementia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Frontotemporal Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Frontotemporal Dementia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Frontotemporal Dementia drugs and therapies

Frontotemporal Dementia Pipeline Market Drivers

• Increasing prevalence of geriatric population, increasing drug development grants, increasing collaborations among companies are some of the important factors that are fueling the Frontotemporal Dementia Market.

Frontotemporal Dementia Pipeline Market Barriers

• However, lack of proper diagnosis, higher chances of misunderstanding with Alzheimer’s disease and other factors are creating obstacles in the Frontotemporal Dementia Market growth.

Scope of Frontotemporal Dementia Pipeline Drug Insight    

• Coverage: Global
• Key Frontotemporal Dementia Companies: Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others
• Key Frontotemporal Dementia Therapies: Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others
• Frontotemporal Dementia Therapeutic Assessment: Frontotemporal Dementia current marketed and Frontotemporal Dementia emerging therapies
• Frontotemporal Dementia Market Dynamics: Frontotemporal Dementia market drivers and Frontotemporal Dementia market barriers 

Request for Sample PDF Report for Frontotemporal Dementia Pipeline Assessment and clinical trials

Table of Contents

1. Frontotemporal Dementia Report Introduction

2. Frontotemporal Dementia Executive Summary

3. Frontotemporal Dementia Overview

4. Frontotemporal Dementia- Analytical Perspective In-depth Commercial Assessment

5. Frontotemporal Dementia Pipeline Therapeutics

6. Frontotemporal Dementia Late Stage Products (Phase II/III)

7. Frontotemporal Dementia Mid Stage Products (Phase II)

8. Frontotemporal Dementia Early Stage Products (Phase I)

9. Frontotemporal Dementia Preclinical Stage Products

10. Frontotemporal Dementia Therapeutics Assessment

11. Frontotemporal Dementia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Frontotemporal Dementia Key Companies

14. Frontotemporal Dementia Key Products

15. Frontotemporal Dementia Unmet Needs

16 . Frontotemporal Dementia Market Drivers and Barriers

17. Frontotemporal Dementia Future Perspectives and Conclusion

18. Frontotemporal Dementia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Frontotemporal Dementia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, MOA, ROA by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio

DelveInsight’s “Gastric Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastric Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastric Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

To Know in detail about the Gastric Neuroendocrine Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastric Neuroendocrine Tumors Market Forecast

Some of the key facts of the Gastric Neuroendocrine Tumors Market Report

• The Gastric Neuroendocrine Tumors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)  
• G-NETs are rare gastric tumors, and the diagnosis is usually accidental. Hence, they are often diagnosed in later stages. However, the number of diagnosed NETs has been increasing for years
• According to the American Society of Clinical Oncology (ASCO), out of all gastrointestinal NETs, 2–4% are found in the stomach
• Type I and Type III account for 70–80% and 15–20% of the total cases of G-NET, respectively. Type II is very rare, and recently Type IV is identified in some studies 
• According to a review article by Ahmed et al. (2020), NETs constitute only 0.5% of all malignant conditions and 2% of all malignant tumors of the Gastrointestinal
• Solucin (n.c.a. 177Lu-Edotreotide/n.c.a. 177Lu-DOTATOC), RRx-001 and Abemaciclib are the most anticipated emerging products for the Gastric Neuroendocrine Tumors treatment, that are in the mid or late phase of clinical trials awaiting approval 
• Key Gastric Neuroendocrine Tumors Companies: Ipsen, Taproot Health, Camurus AB, Novartis Pharmaceuticals, and others 
• Key Gastric Neuroendocrine Tumors Therapies: Ribociclib, CAM2029, Lutathera, Octreotide LAR, Satoreotide trizoxetan, and others 
• The Gastric Neuroendocrine Tumors epidemiology based on gender analyzed that around 60% of the cases of G-NET found in the SEER database were females  

Request a sample for the Gastric Neuroendocrine Tumors Market Report:

https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Gastric Neuroendocrine Tumors Overview

According to the Neuroendocrine Tumor Patient Foundation (n.d.)- “Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into tumor”.

Gastric Neuroendocrine Tumors Epidemiology Segmentation:

The Gastric Neuroendocrine Tumors market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Gastric Neuroendocrine Tumors
• Prevalent Cases of Gastric Neuroendocrine Tumors by severity
• Gender-specific Prevalence of Gastric Neuroendocrine Tumors
• Diagnosed Cases of Episodic and Chronic Gastric Neuroendocrine Tumors 

Download the report to understand which factors are driving Gastric Neuroendocrine Tumors epidemiology trends @ Gastric Neuroendocrine Tumors Epidemiological Insights

Gastric Neuroendocrine Tumors Market  

The dynamics of the Gastric Neuroendocrine Tumors market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as CAM2029, Lutathera, and others during the forecasted period 2019-2032.

Gastric Neuroendocrine Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastric Neuroendocrine Tumors market or expected to get launched during the study period. The analysis covers Gastric Neuroendocrine Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastric Neuroendocrine Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastric Neuroendocrine Tumors Therapies

• Ribociclib
• CAM2029
• Lutathera
• Octreotide LAR
• Satoreotide trizoxetan

Gastric Neuroendocrine Tumors Key Companies 

• Ipsen
• Taproot Health
• Camurus AB
• Novartis Pharmaceuticals

To know more about Gastric Neuroendocrine Tumors treatment, visit @ Gastric Neuroendocrine Tumors Medications 

Scope of the Gastric Neuroendocrine Tumors Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastric Neuroendocrine Tumors Companies: Ipsen, Taproot Health, Camurus AB, Novartis Pharmaceuticals, and others
• Key Gastric Neuroendocrine Tumors Therapies: Ribociclib, CAM2029, Lutathera, Octreotide LAR, Satoreotide trizoxetan, and others
• Therapeutic Assessment: Gastric Neuroendocrine Tumors current marketed and Gastric Neuroendocrine Tumors emerging therapies
• Gastric Neuroendocrine Tumors Market Dynamics: Gastric Neuroendocrine Tumors market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gastric Neuroendocrine Tumors Unmet Needs, KOL’s views, Analyst’s views, Gastric Neuroendocrine Tumors  Market Access and Reimbursement 

Discover more about therapies set to grab major Gastric Neuroendocrine Tumors market share @ Gastric Neuroendocrine Tumors market forecast

Table of Contents 

1. Gastric Neuroendocrine Tumors Market Report Introduction

2. Executive Summary for Gastric Neuroendocrine Tumors

3. SWOT analysis of Gastric Neuroendocrine Tumors

4. Gastric Neuroendocrine Tumors Patient Share (%) Overview at a Glance

5. Gastric Neuroendocrine Tumors Market Overview at a Glance

6. Gastric Neuroendocrine Tumors Disease Background and Overview

7. Gastric Neuroendocrine Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastric Neuroendocrine Tumors 

9. Gastric Neuroendocrine Tumors Current Treatment and Medical Practices

10. Gastric Neuroendocrine Tumors Unmet Needs

11. Gastric Neuroendocrine Tumors Emerging Therapies

12. Gastric Neuroendocrine Tumors Market Outlook

13. Country-Wise Gastric Neuroendocrine Tumors Market Analysis (2019–2032)

14. Gastric Neuroendocrine Tumors Market Access and Reimbursement of Therapies

15. Gastric Neuroendocrine Tumors Market drivers

16. Gastric Neuroendocrine Tumors Market barriers

17.  Gastric Neuroendocrine Tumors Appendix

18. Gastric Neuroendocrine Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastric Neuroendocrine Tumors Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Ipsen, Taproot Health, Camurus AB, Novartis

DelveInsight’s “Heparin-induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Heparin-induced Thrombocytopenia, historical and forecasted epidemiology as well as the Heparin-induced Thrombocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

To Know in detail about the Heparin-induced Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Heparin-induced Thrombocytopenia Market Forecast

Heparin-induced Thrombocytopenia Market Report’s Key Highlights:

• The Heparin-induced Thrombocytopenia market size was valued approximately USD 125 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• With almost half of the 7MM’s total market size in 2022, the United States had the biggest share of any country in the group.
• With a market share of almost 77% of all marketed pharmaceuticals, Argatroban had the largest market size in the United States in 2022.
• Key Heparin-induced Thrombocytopenia Companies: Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma, and others
• Key Heparin-induced Thrombocytopenia Therapies: argatroban, VLX-1005, bivalirudin, Desirudin (Iprivask™), and others
• The Heparin-induced Thrombocytopenia epidemiology based on gender analyzed that higher number of cases of Heparin-induced Thrombocytopenia were observed in males as compared to females
• The Heparin-induced Thrombocytopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Heparin-induced Thrombocytopenia pipeline products will significantly revolutionize the Heparin-induced Thrombocytopenia market dynamics

Request a sample for the Heparin-induced Thrombocytopenia Market Report:

https://www.delveinsight.com/report-store/heparin-induced-thrombocytopenia-market

Heparin-induced Thrombocytopenia Country based Treatment Analysis: 

The Heparin-induced Thrombocytopenia treatment market report provides treatment regimen across the 7MM. It will help companies to analyze the practices followed across 7MM, patient journey and advances in Heparin-induced Thrombocytopenia Therapies that have the potential to transform cancer treatment paradigms and improve patient outcomes.

Heparin-induced Thrombocytopenia Epidemiology Insights: 

The report offers historical and forecasted epidemiology insights that helps to understand the target patient population for Heparin-induced Thrombocytopenia. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patients pools. The epidemiology in report is segmented as : 

Heparin-induced Thrombocytopenia Epidemiology Segmentation:

• Total Prevalence of Heparin-induced Thrombocytopenia
• Prevalent Cases of Heparin-inducedThrombocytopenia by severity
• Gender-specific Prevalence of Heparin-induced Thrombocytopenia
• Diagnosed Cases of Episodic and Chronic Heparin-induced Thrombocytopenia

“As per DelveInsight, Heparin-Induced Thrombocytopenia Was reported in around 111,000 incident cases in 2022; however, by 2032, the number of cases is predicted to rise in the US.In the United States, there were approximately 63,000 occurrences of thrombosis in heparin-induced thrombocytopenia (HIT) in 2022. This number is predicted to rise at a moderate annual growth rate (CAGR) by 2032.

Japan recorded around 7,700 incident cases of Heparin-Induced Thrombocytopenia (HIT) in 2022. In Japan, these instances are predicted to rise at a moderate CAGR by 2032.”

Download the report to understand which factors are driving Heparin-induced Thrombocytopenia epidemiology trends @ Heparin-induced Thrombocytopenia Epidemiology Forecast

Emerging Heparin-induced Thrombocytopenia drugs Uptake:

• VLX-1005, a novel treatment for Heparin-induced Thrombocytopenia (HIT), is presently undergoing Phase II clinical studies. The few main therapies for HIT that are now available are listed below.
• There are also a number of new oral anticoagulants on the market, such as dabigatran, apixaban, and rivaroxaban, and preliminary data indicates that they could be helpful for HIT, especially in situations where conventional treatments are ineffective. None of these medications have FDA approval for use in HIT, and their efficacy in treating individuals with HIT has not yet been thoroughly evaluated.
• VLX-1005 was given Fast Track Designation (FTD) by the FDA in June 2022 in order to treat heparin-induced thrombocytopenia

Heparin-induced Thrombocytopenia Market Forecast :

• The research includes a thorough analysis of the past and projected markets for Heparin-induced Thrombocytopenia (HIT), which includes pharmacological outreach in the 7MM nations.
• Rise in the cases of heparin-induced thrombocytopenia due to various risk factors, such as increased cardiac and orthopedic surgeries and the continued use of unfractionated heparin in hospitalized patients
• The emergence of direct oral anticoagulants (DOACs) as an alternative for parenteral anticoagulants in acute HIT or HIT with thrombosis is a significant strength in the HIT market. DOACs offer convenience, ease of administration, and comparable efficacy to traditional parenteral anticoagulants 

Heparin-induced Thrombocytopenia Therapies and Key Companies

• argatroban: Mitsubishi Tanabe Pharma
• VLX-1005: Veralox Therapeutics
• bivalirudin: The Medicines Company
• Desirudin (Iprivask™): Canyon Pharma

Discover more about therapies set to grab major Heparin-induced Thrombocytopenia market share @ Heparin-induced Thrombocytopenia Treatment Market

Scope of the Heparin-induced Thrombocytopenia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Heparin-induced Thrombocytopenia Companies: Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
• Key Heparin-induced Thrombocytopenia Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
• Heparin-induced Thrombocytopenia Therapeutic Assessment: Heparin-induced Thrombocytopenia current marketed and Heparin-induced Thrombocytopenia emerging therapies
• Heparin-induced Thrombocytopenia Market Dynamics: Heparin-induced Thrombocytopenia market drivers and Heparin-induced Thrombocytopenia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Heparin-induced Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Heparin-induced Thrombocytopenia Market Access and Reimbursement 

DelveInsight’s report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Heparin-induced Thrombocytopenia market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the heparin-induced thrombocytopenia market, including the competitive environment, key companies developing drugs for Heparin-induced Thrombocytopenia, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the heparin-induced thrombocytopenia market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing  with  Heparin-induced Thrombocytopenia. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing – reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the heparin-induced thrombocytopenia market with clarity and purpose.

Discover more about therapies set to grab major Heparin-induced Thrombocytopenia market share @ Heparin-induced Thrombocytopenia market forecast 

Table of Contents

1. Heparin-induced Thrombocytopenia Report Introduction

2. Heparin-induced Thrombocytopenia Executive Summary

3. Heparin-induced Thrombocytopenia Overview

4. Heparin-induced Thrombocytopenia- Analytical Perspective In-depth Commercial Assessment

5. Heparin-induced Thrombocytopenia Pipeline Therapeutics

6. Heparin-induced Thrombocytopenia Late Stage Products (Phase II/III)

7. Heparin-induced Thrombocytopenia Mid Stage Products (Phase II)

8. Heparin-induced Thrombocytopenia Early Stage Products (Phase I)

9. Heparin-induced Thrombocytopenia Preclinical Stage Products

10. Heparin-induced Thrombocytopenia Therapeutics Assessment

11. Heparin-induced Thrombocytopenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Heparin-induced Thrombocytopenia Key Companies

14. Heparin-induced Thrombocytopenia Key Products

15. Heparin-induced Thrombocytopenia Unmet Needs

16 . Heparin-induced Thrombocytopenia Market Drivers and Barriers

17. Heparin-induced Thrombocytopenia Future Perspectives and Conclusion

18. Heparin-induced Thrombocytopenia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Heparin Induced Thrombocytopenia Market to Witness Growth by 2032, Estimates DelveInsight | Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma

DelveInsight’s “Glaucoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glaucoma Market Forecast

Some of the key facts of the Glaucoma Market Report: 

• The Glaucoma market size was valued approximately USD 4,073 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In June 2023, Ciliatech’s implantable device for glaucoma patients is nearing regulatory approval following the disclosure of favorable outcomes from a subsequent two-year post-operative clinical trial.
• In 2022, the Glaucoma market in the US stood out with the highest market size, reaching USD 2,571 million in net sales revenue among the 7MM. Conversely, the UK exhibited the lowest market size, with approximately USD 132 million.
• In 2022, it was estimated that there were approximately 7,045,443 diagnosed prevalent cases of Glaucoma in the 7MM. However, the total burden of Glaucoma, including both diagnosed and undiagnosed cases, was estimated to be around 16,632,421 in the same year across the 7MM.
• The overall Glaucoma market size is projected to increase in the forecast period, driven by the anticipated introduction of emerging therapies such as iDose TR (travoprost intraocular implant), NCX 470, PDP-71, and other treatments.
• Glaucoma often goes unnoticed in a majority of patients due to various factors. DelveInsight’s estimates indicate that out of the 16,632,421 prevalent Glaucoma cases in the 7MM in 2022, only around 7,045,443 cases are believed to have been formally diagnosed.
• Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
• Key Glaucoma Therapies: PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
• Glaucoma can impact individuals of both genders, but the ratio of male to female Glaucoma patients indicates a higher prevalence among females. In 2022, there were approximately 3,234,796 cases of Glaucoma among males and 3,810,646 cases among females.
• The Glaucoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glaucoma pipeline products will significantly revolutionize the Glaucoma market dynamics.

Glaucoma Overview

Glaucoma is a disease that damages the eye’s optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment. There are two main types of glaucoma – primary and secondary

Get a Free sample for the Glaucoma Market Report:

https://www.delveinsight.com/report-store/glaucoma-market

Glaucoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glaucoma Epidemiology Segmentation:

The Glaucoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Glaucoma
• Prevalent Cases of Glaucoma by severity
• Gender-specific Prevalence of Glaucoma
• Diagnosed Cases of Episodic and Chronic Glaucoma

Download the report to understand which factors are driving Glaucoma epidemiology trends @ Glaucoma Epidemiology Forecast

Glaucoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glaucoma market or expected to get launched during the study period. The analysis covers Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glaucoma Therapies and Key Companies

• NCX-470: Nicox Ophthalmics
• TRS01: Tarsier Pharma
• PDP-716: SPARC
• PRO-122: Laboratories Sophia
• EYBELIS/Omidenepag isopropyl/DE-117: Santen Pharmaceutical
• DE-130A: Santen Pharmaceutical
• Sepetaprost (DE-126/ONO9054): Santen Pharmaceutical
• Nyxol: Ocuphire Pharma
• K-232: Kowa
• Aflibercept (Eylea, BAY 86-5321): Bayer
• Travoprost: Alcon Research
• Timolol: Pfizer
• timolol/dorzolamide: Merck Sharp & Dohme LLC
• QPI-1007: Quark Pharmaceuticals

Discover more about therapies set to grab major Glaucoma market share @ Glaucoma Treatment Market

Glaucoma Market Drivers

• Rich emerging pipeline
• Development of advanced antiglaucoma medications
• Development of treatment methods to tackle the situation of non-adherence
• Patients-friendly dosage regimes
• Rise in awareness

Glaucoma Market Barriers

• Approaches to clinical practice
• Socioeconomic barriers
• Lack of patient pool due to under diagnosis

Scope of the Glaucoma Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
• Key Glaucoma Therapies: PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
• Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
• Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Glaucoma Unmet Needs, KOL’s views, Analyst’s views, Glaucoma Market Access and Reimbursement 

To know more about Glaucoma companies working in the treatment market, visit @ Glaucoma Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Glaucoma Market Report Introduction

2. Executive Summary for Glaucoma

3. SWOT analysis of Glaucoma

4. Glaucoma Patient Share (%) Overview at a Glance

5. Glaucoma Market Overview at a Glance

6. Glaucoma Disease Background and Overview

7. Glaucoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Glaucoma 

9. Glaucoma Current Treatment and Medical Practices

10. Glaucoma Unmet Needs

11. Glaucoma Emerging Therapies

12. Glaucoma Market Outlook

13. Country-Wise Glaucoma Market Analysis (2020–2034)

14. Glaucoma Market Access and Reimbursement of Therapies

15. Glaucoma Market Drivers

16. Glaucoma Market Barriers

17.  Glaucoma Appendix

18. Glaucoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glaucoma Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Bayer, SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire

DelveInsight’s “Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Reflux Disease Market Forecast

Some of the key facts of the Gastroesophageal Reflux Disease Market Report: 

• The Gastroesophageal Reflux Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2024, Implantica commenced the premarket approval process with the US Food and Drug Administration (FDA) for its RefluxStop treatment intended for gastroesophageal reflux disease (GERD). The Liechtenstein-based company aims to obtain approval for RefluxStop through the US FDA’s premarket approval application (PMA) modular review program. This approach permits companies to complete sections, known as modules, at various intervals. Final confirmation is granted once all sections of the PMA are completed. Additionally, the program facilitates ongoing review and feedback from the FDA as modules are submitted.
• In May 2023, Phathom Pharmaceuticals refiled its New Drug Application with the FDA for vonoprazan, aiming to secure approval for treating erosive gastroesophageal reflux disease (GERD), also known as erosive esophagitis.
• According to Marco G. Patti (2020), a significant portion of Americans, estimated at 25% to 40%, encounter symptomatic gastroesophageal reflux disease (GERD) at various times, with approximately 7% to 10% experiencing daily symptoms. While many manage their symptoms using over-the-counter (OTC) medications and without seeking medical advice, the actual GERD prevalence is likely higher.
• Key Gastroesophageal Reflux Disease Companies: Phantom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
• Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
• The Gastroesophageal Reflux Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.

Gastroesophageal Reflux Disease Overview

Gastroesophageal Reflux Disease (GERD) is a chronic digestive disorder characterized by the reflux of stomach acid into the esophagus, causing irritation and inflammation. It occurs when the lower esophageal sphincter (LES), a ring of muscle between the esophagus and stomach, becomes weak or relaxes inappropriately, allowing stomach contents to flow back up into the esophagus.

Get a Free sample for the Gastroesophageal Reflux Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Gastroesophageal Reflux Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroesophageal Reflux Disease Epidemiology Segmentation:

The Gastroesophageal Reflux Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Gastroesophageal Reflux Disease
• Prevalent Cases of Gastroesophageal Reflux Disease by severity
• Gender-specific Prevalence of Gastroesophageal Reflux Disease
• Diagnosed Cases of Episodic and Chronic Gastroesophageal Reflux Disease

Download the report to understand which factors are driving Gastroesophageal Reflux Disease epidemiology trends @ Gastroesophageal Reflux Disease Epidemiology Forecast

Gastroesophageal Reflux Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Reflux Disease market or expected to get launched during the study period. The analysis covers Gastroesophageal Reflux Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroesophageal Reflux Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroesophageal Reflux Disease Therapies and Key Companies

• Vonoprazan: Phathom Pharmaceuticals
• X842: Sinorda Biomedicine
• BLI5100: Sebela Pharmaceutical
• Linaprazan glurate: Cinclus Pharma
• Naronapride: Renexxion Ireland
• Fexuprazan: Daewoong Pharmaceutical
• IN-C003: HK inno.N
• IN-C002: HK inno.N
• CKD-382: Chong Kun Dang Pharmaceutical
• IN-C004: HK inno.N
• AD-214: Addpharma
• JP-1366: Jeil Pharmaceuticals
• Naronapride: Renexxion
• Fexuprazan: Daewoong Pharmaceutical

Discover more about therapies set to grab major Gastroesophageal Reflux Disease market share @ Gastroesophageal Reflux Disease Treatment Landscape

Gastroesophageal Reflux Disease Market Strengths

• Lifestyle changes, including dietary adjustments, weight management, and elevating the head of the bed, offer non-pharmacological approaches to managing GERD and reducing symptom severity.
• There is a growing awareness of GERD among both healthcare professionals and the general population. This increased awareness leads to earlier diagnosis and improved management.

Gastroesophageal Reflux Disease Market Opportunities

• Multidisciplinary teams involving gastroenterologists, dietitians, psychologists, and surgeons can work collaboratively to provide comprehensive care and support for GERD patients.
• Promising new drugs, such as naronapride, vonoprazan, and BLI5100 are being developed to address GERD and its complications, providing potential alternatives for patients who are unresponsive to current treatments.

Scope of the Gastroesophageal Reflux Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastroesophageal Reflux Disease Companies: Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
• Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
• Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies
• Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gastroesophageal Reflux Disease Unmet Needs, KOL’s views, Analyst’s views, Gastroesophageal Reflux Disease Market Access and Reimbursement 

To know more about Gastroesophageal Reflux Disease companies working in the treatment market, visit @ Gastroesophageal Reflux Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Gastroesophageal Reflux Disease Market Report Introduction

2. Executive Summary for Gastroesophageal Reflux Disease

3. SWOT analysis of Gastroesophageal Reflux Disease

4. Gastroesophageal Reflux Disease Patient Share (%) Overview at a Glance

5. Gastroesophageal Reflux Disease Market Overview at a Glance

6. Gastroesophageal Reflux Disease Disease Background and Overview

7. Gastroesophageal Reflux Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroesophageal Reflux Disease 

9. Gastroesophageal Reflux Disease Current Treatment and Medical Practices

10. Gastroesophageal Reflux Disease Unmet Needs

11. Gastroesophageal Reflux Disease Emerging Therapies

12. Gastroesophageal Reflux Disease Market Outlook

13. Country-Wise Gastroesophageal Reflux Disease Market Analysis (2019–2032)

14. Gastroesophageal Reflux Disease Market Access and Reimbursement of Therapies

15. Gastroesophageal Reflux Disease Market Drivers

16. Gastroesophageal Reflux Disease Market Barriers

17.  Gastroesophageal Reflux Disease Appendix

18. Gastroesophageal Reflux Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroesophageal Reflux Disease Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Phantom Pharmaceuticals, Sinorda Biomed

DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Bowel Disease Market Forecast

Some of the key facts of the Inflammatory Bowel Disease Market Report: 

• The Inflammatory Bowel Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2023, Insilico Medicine, a clinical-stage biotechnology company employing generative artificial intelligence (AI), has launched the inaugural human trial for ISM5411. This compound, a poly hydroxylase domain (PHD) 1/2 inhibitor, holds promise as a pioneering treatment for inflammatory bowel disease (IBD).
• During the year 2021, there were 3,835,000 prevalent cases of IBD in the 7MM. In all of the regions, this count is predicted to rise during the projection period
• There were 634,000 and 1,021,000 prevalent cases of CD and UC, respectively, in the EU-5 region in 2021
• It was discovered that the overall diagnosed prevalence of IBD in the 7MM increased steadily during the course of the study. In the 7MM, 2,743,000 cases of IBD were identified in 2021. In 2021, there were the most diagnosed cases of IBD in the United States. In the US, there were over 1,323,000 diagnosed cases of IBD in 2021
• The introduction of numerous important medications during the past ten years has changed how inflammatory bowel disease is managed. Adalimumab, infliximab, and vedolizumab medications like HUMIRA (adalimumab, AbbVie), REMICADE (Janssen), and ENTYVIO (Takeda) have all assisted patients in achieving significant endpoints including clinical remission and mucosal healing.
• Key Inflammatory Bowel Disease Companies: Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
• Key Inflammatory Bowel Disease Therapies: Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others
• The Inflammatory Bowel Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.

Inflammatory Bowel Disease Overview

Chronic and complicated, inflammatory bowel disease (IBD) is brought on by immune system dysregulation brought on by genetic, epigenetic, microbial, and environmental variables.

Get a Free sample for the Inflammatory Bowel Disease Market Report:

https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market

Inflammatory Bowel Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Inflammatory Bowel Disease Epidemiology Segmentation:

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Inflammatory Bowel Disease
• Prevalent Cases of Inflammatory Bowel Disease by severity
• Gender-specific Prevalence of Inflammatory Bowel Disease
• Diagnosed Cases of Episodic and Chronic Inflammatory Bowel Disease

Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ Inflammatory Bowel Disease Epidemiology Forecast

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammatory Bowel Disease Therapies and Key Companies

• Mirikizumab: Eli Lilly and Company
• Filgotinib: Gilead/ Galapagos
• AMT-101: Applied Molecular Transport
• PN-943: Protagonist Therapeutics
• Tremfya: Janssen
• Brazikumab: AstraZeneca

Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ Inflammatory Bowel Disease Treatment Market

Scope of the Inflammatory Bowel Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Inflammatory Bowel Disease Companies: Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
• Key Inflammatory Bowel Disease Therapies: Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others
• Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies
• Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Inflammatory Bowel Disease Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Bowel Disease Market Access and Reimbursement 

To know more about Inflammatory Bowel Disease companies working in the treatment market, visit @ Inflammatory Bowel Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Inflammatory Bowel Disease Market Report Introduction

2. Executive Summary for Inflammatory Bowel Disease

3. SWOT analysis of Inflammatory Bowel Disease

4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance

5. Inflammatory Bowel Disease Market Overview at a Glance

6. Inflammatory Bowel Disease Disease Background and Overview

7. Inflammatory Bowel Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Bowel Disease 

9. Inflammatory Bowel Disease Current Treatment and Medical Practices

10. Inflammatory Bowel Disease Unmet Needs

11. Inflammatory Bowel Disease Emerging Therapies

12. Inflammatory Bowel Disease Market Outlook

13. Country-Wise Inflammatory Bowel Disease Market Analysis (2019–2032)

14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies

15. Inflammatory Bowel Disease Market Drivers

16. Inflammatory Bowel Disease Market Barriers

17.  Inflammatory Bowel Disease Appendix

18. Inflammatory Bowel Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Bowel Disease Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport